Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity.

Authors :: Bae JH
Cho YM
Source :: Journal of diabetes investigation [J Diabetes Investig] 2025 Feb; Vol. 16 (2), pp. 183-186. Date of Electronic Publication: 2024 Oct 26.
Publication Year :: 2025
Abstract: Several ongoing trials are evaluating incretin-based therapies, including GLP-1 receptor agonists, for their effects on CKD and MASLD. These studies will offer insights into their potential for metabolic diseases in people with type 2 diabetes and obesity.<br /> (© 2024 The Author(s). Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.)

Subjects :: Humans
Liver Diseases drug therapy
Glucagon-Like Peptide-1 Receptor
Kidney Diseases drug therapy
Kidney Diseases etiology
Hypoglycemic Agents therapeutic use
Diabetes Mellitus, Type 2 drug therapy
Incretins therapeutic use
Obesity drug therapy
Obesity complications

Full Text Access

Tools